Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
5Customers
2Debt Items
18Related Chains
Source-Backed Evidence Depth
Aurinia Pharmaceuticals Inc. (AUPH) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
10Total relationships
1Distinct source URLs
5High confidence
0.810Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Reciprocal relationship from VERA graph: Reciprocal relationship from AUPH graph: Reciprocal relationship from VERA graph: competing technological and market developments; • maintaining our rights un…
Reciprocal relationship from ACAD graph: . Under the terms of the agreement, the Company paid Stoke a $ 60.0 million upfront payment which was accounted for as an asset acquisition and was expensed t…
Aurinia Pharmaceuticals Inc. Customers
Ticker
Name
Confidence
Evidence
OTSUKA
OTSUKA
95%
In August 2022, the Company entered into a commercial supply agreement with Otsuka to: (i) supply LUPKYNIS inventory to Otsuka at cost plus a margin; and (ii) provide manufacturing and other services…
OTSUKA-PHARMACEUTICAL-CO-LTD
OTSUKA-PHARMACEUTICAL-CO-LTD
95%
Aurinia sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. ("Otsuka"), for the European and Japanese market.
KZR
Kezar Life Sciences, Inc.
72%
Reciprocal relationship from KZR graph: Reciprocal relationship from AUPH graph: Reciprocal relationship from KZR graph: Reciprocal relationship from AUPH graph: Reciprocal relationship from KZR grap…
KZR
Kezar Life Sciences, Inc.
72%
Item 1 of Part II Legal Proceedings. 6. Deferred Compensation and Other Noncurrent Liabilities In March 2012, the Company entered into employee retention arrangements with certain former executive of…
Reciprocal relationship from VERA graph: experienced any significant delays in obtaining any raw materials from our suppliers, we cannot provide assurance that we will not face shortages from one or …
Aurinia Pharmaceuticals Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
AUPH-DEBT-7974
Warrants outstanding: 0
90%
xbrl warrant detail from xbrl 2022-12-31.
AUPH-DEBT
Debt stack $68.6M
90%
Market cache reports total debt of $68.6M.
Aurinia Pharmaceuticals Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Aurinia Pharmaceuticals Inc..
Aurinia Pharmaceuticals Inc. Ownership
Holder
Name
Confidence
Evidence
AUPH-OWNER-TANG-CAPITAL-MANAGEMENT-LLC
TANG CAPITAL MANAGEMENT LLC
90%
13F overlay lists TANG CAPITAL MANAGEMENT LLC as top holder; 261 tracked holders.
Aurinia Pharmaceuticals Inc. Extended Supply Chain Network
